OSI PHARMACEUTICALS, INC. for OSI PHARMACEUTICALS, INC.
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Oral oncology treatment coverage by insurance companies - HR 2366, Drug Coverage Parity Act of 2009
Foreign entity interest: OSI Pharmaceuticals was recently acquired by Astellas Pharma Inc. Accordingly, Astellas Pharma, Inc, as OSI's owner, has an interest as a pharmaceutical company in all of the issues with respect to which OSI has lobbied and listed above.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KIMBERLY LINTHICUM | — |
Medicare/Medicaid MMM
Medicare Part D coverage gap implementation, implementation of Medicaid rebate increases & expansions - Patient Protection and Affordable Care Act (HR 3590/PL 111-148) and Health Care and Education Reconciliation Act of 2010 (HR 4872/PL 111-152)
Foreign entity interest: OSI Pharmaceuticals was recently acquired by Astellas Pharma Inc. Accordingly, Astellas Pharma, Inc, as OSI's owner, has an interest as a pharmaceutical company in all of the issues with respect to which OSI has lobbied and listed above.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KIMBERLY LINTHICUM | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.